Parsippany-Based Surgical Company Receives Go Ahead to Market Limb Salvage System

PARSIPPANY, N.J.– The U.S. Food and Drug Administration (FDA) cleared Parsipanny-based Onkos Surgical, to market its ELEOS™ Limb Salvage System to treat patients with significant bone loss, according to a press release from the company.

"Surgical Oncology has been an underserved market for some time," said Onkos Surgical Founder and Chief Executive Officer Patrick Treacy. "These surgeons and patients deserve more. With the introduction of the ELEOS Limb Salvage System, we will continue to buildon our promise of delivering meaningful innovation in the orthopedic oncology market. Our company is focused and dedicated to bringing solutions to this group of surgeons and patients that will address the significant unmet need that exists. Today is a very important milestone for our company and we look forward to executing on our robust pipeline
of innovation."
Added Onkos Surgical Surgeon Advisory Board Member Dr. Steven Gitelis: "Tumor surgery is often personalized as each patient presents differently.
"When replacing bone with an implant, ELEOS provides the flexibility and modularity a surgeon needs for these complex cases, added the professor and vice chairman for the Department of Orthopedic Surgery at Rush University Medical Center. "ELEOS system is a long term reconstructive option for oncology patients. Our patient population is unique and we need a company like Onkos to provide innovation where we have our most challenging need.".

Onkos is planning a full launch during early 2017, according to Treacy.

Onkos Surgical was founded in 2015.

Image via Shutterstock